Pure Global

Everolimus Eluting Coronary Stent System - India CDSCO Medical Device Registration

Everolimus Eluting Coronary Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID G/28/1379_c87d460d00d3564b32bb8aea8cee3662_6384974c9ab51edb275330c727ff5fa6. This device is marketed under the brand name Evader, Evernic, Evernia, Everton. The license holder is Veritas Bioventions Pvt. Ltd, and it is classified as Device Class Class D. The approving authority is Central Drug Standards Control Organization, Ahmedabad.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class D
Everolimus Eluting Coronary Stent System
UID: G/28/1379_c87d460d00d3564b32bb8aea8cee3662_6384974c9ab51edb275330c727ff5fa6

Brand Name

Evader, Evernic, Evernia, Everton

Device Class

Class D

Approving Authority

Central Drug Standards Control Organization, Ahmedabad

Product Information

The Coronary Stent is indicated for elective implantation and for treatment of acute or threatened closure following intervention in the coronary vasculature, including saphenous vein grafts & is intended to improve coronary luminal diameter. The issues of repeated restenosis are always big problem in metallic stent and to overcome this issue Drug eluting Stents (Evader, Evernic, Evernia, Everton) are use for angioplasty. The Everolimus eluting coronary stent system (Evader, Evernic, Evernia, Everton) is indicated for use in patients with symptomatic ischemic heart disease due to discrete de novo coronary artery lesions with a reference vessel. Diameter ranging from 2.25 mm to 4.0 mm and is intended to improve coronary luminal diameter. Everolimus drug inhibits growth factor and cytokine stimulated cell proliferation and prevents vascular hyperplasia in allograft and angioplasty models. Also Everolimus modulates inflammatory cell function and blocks smooth muscle cell proliferation. By not killing cells, it prevents vessel damage and allows rapid and complete re-endothelization within 30 days. Everolimus thereby minimizes the potential for thrombosis.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing